Nicholas Goldner, PhD

We are creating a global angel investor network, through which we can share deal-flow, expertise and contacts.

Alix Ventures: Driving Patient Impact - Supporting early stage Life Science startups engineering biology to drive radical advances in human health Born from our collective experience as founders, we set out to build the fund we wanted to raise from... Thesis: Life Sciences is experiencing rapid innovation with the rise of new generation of companies known as “TechBio” (Merging technology & biology), a change we believe is leading to some of the most impactful solutions in decades. Our passion is to help build transformative companies ahead of this revolution to significantly impact the quality & effectiveness of patient care. We aim to partner with passionate, accomplished founders who possess unique insights to solve some of the world’s most daring problems facing us in Life Sciences. Team: Our entire team is built of Life Science Founders with experience in raising capital, scaling teams, running labs, partnering with Pharma, & the many fires that consist of operating an early stage company. Founders, we’d love to partner with you along the journey & help translate daunting ideas into world shaping innovations - here’s to a better brighter future for patients! SAB: Composed of Bioengineering PhDs turned Founders, our Scientific Advisory Board provides deep technical expertise & fluency across a wide variety of Life Science sub-domains from platforms for “Novel Applications” (Therapeutics/Diagnostics) to “Bio-Economy Infrastructure” (Tools/Services/Manufacturing). Let’s talk science! Support: Helping our founders is our utmost priority. To tackle the many challenges ahead, we’ve curated a full platform of resources to help with customer introductions, fundraising, & team building, amongst others. In addition, dedicated to supporting our portfolio is our extensive network of industry executives spanning Top 25 Pharma, major health systems, & large Payors.

Helping patients fight treatment-resistant cancer. resistanceBio can discover and overcome clinical treatment resistance pre-clinically.

We are creating a global angel investor network, through which we can share deal-flow, expertise and contacts.

We are a fund of 500+ Y Combinator alumni working together to invest in top Y Combinator startups. Our portfolio has gone on to raise from Andreessen Horowitz, Accel, Sequoia, Khosla, Lux, First Round, Initialized, Founders Fund, and many other top VCs. https://www.pioneerfund.vc

Were Hiring! Resistance Resistant Treatments: A New Class of Therapeutics